Adult Acute Eosinophilic Leukemia (DBCOND0029225)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT01550185	Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia	Eltrombopag	treatment	1	terminated
NCT00352365	Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia	Lenalidomide	treatment	2	completed
NCT02071901	Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy	Eltrombopag	supportive_care	2	unknown_status
NCT00027872	Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	Tipifarnib	treatment	2	completed
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00089388	Cilengitide in Treating Patients With Acute Myeloid Leukemia	Cilengitide	treatment	2	terminated
NCT00006363	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	Aldesleukin Busulfan Cytarabine Daunorubicin Etoposide Filgrastim Valspodar	treatment	3	completed
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Cytarabine Idarubicin Tipifarnib	treatment	1 / 2	completed
NCT00096148	Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Bevacizumab Cytarabine Idarubicin	treatment	2	terminated
NCT00407966	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	2	completed
NCT00383474	Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase	Bortezomib Bortezomib D-mannitol Tipifarnib	treatment	1	completed
NCT00101231	Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Alvocidib	treatment	1	terminated
NCT00131989	Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT01159301	Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	Entinostat Sorafenib	treatment	1	terminated
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00217646	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT01260714	Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia	Azacitidine Beta-D-Glucose Etoposide Mitoxantrone	treatment	1	terminated